AstraZeneca Investor Day
AstraZeneca hosted an Investor Day for institutional investors and financial analysts held on Tuesday 18th November 2014. Presentations were made from Pascal Soriot and his management team that provided an updated view of AstraZeneca’s strategy and plans to return to growth and scientific leadership in our chosen areas.
Third quarter and nine months results 2014
Download our third quarter 2014 presentation and clinical trial programmes summary.
Fourth quarter and full year results 2013
JP Morgan Healthcare Conference
Pascal Soriot, Chief Executive Officer, AstraZeneca presented an update on the company’s development pipeline and outline its strategic priorities for 2014 as AstraZeneca continues to focus on achieving scientific leadership and returning to growth.
Fostamatinib analyst briefing
Third quarter and nine months results 2012
Download presentation and analyst call script.
Latest results and presentations
Annual Report websites
Our Annual Report provides a wide range of information about our global business and how we are working, both within the company and in partnership with others, to meet complex healthcare challenges and deliver life-changing medicines for people worldwide.
I/O combo data updated at SITC - durvalumab plus tremelimumab combination data in lung cancer (6 November 2015)
AstraZeneca Investor Relations Team's Briefing Note regarding updated combination data presented at the Society for Immunotherapy in Cancer (SITC) on Friday 6 November 2015.
AstraZeneca refines its financial reporting in line with evolving business model (6 March 2015)
AstraZeneca announced an update to the presentation of its Statement of Comprehensive Income, which will see revenue from externalisation becoming more visible to enhance transparency for investors.
Accounting for the US Branded Pharmaceutical Fee (7 January 2015)
In mid 2014 the Internal Revenue Service issued final regulations that affected how the annual branded pharmaceutical fee, imposed by the health care reform legislation in 2010 is recognised. As a result, entities covered by the legislation will now accrue for the obligation as each sale occurs. AstraZeneca recorded a catch-up charge to SG&A, reflecting this new basis, as part of its Q3 2014 results.
Diabetes alliance transaction overview (19 December 2014)
UK investor enquiries
Our Annual Report provides a wide range of information about our global business.
Answers to frequently asked shareholder questions.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development